This inventor holds 3 USPTO granted patents. Top assignees: Athenen Therapeutics, Inc., Eliem Therapeutics (UK) Ltd, Eliem Therapeutics, Inc.. Active years: 2020-2023.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Boston, MA (US) (2020)
- Raleigh, NC (US) (2021 - 2023)
Company Filing History:
Years Active: 2020-2023
Certainly! Here's the article about inventor Neil Buckley:
Title: Unveiling the Innovations of Neil Buckley: A Glimpse into Cutting-Edge Neurosteroid Compositions
Introduction:
Neil Buckley, a distinguished inventor based in Raleigh, NC (US), has made significant contributions to the field of neurosteroid compositions, particularly in the realm of GABAreceptor modulation. With a portfolio encompassing 3 patents, Buckley's work stands at the forefront of advancements in neuropharmacology.
Latest Patents:
One of Buckley's latest patents includes groundbreaking compositions that preferentially potentiate subtypes of GABAreceptors, allowing for the selective modulation of specific receptor subtypes. These neurosteroid-based compositions offer novel methods for treating GABAdisorders, showcasing Buckley's innovative approach to neuropharmacological interventions.
Career Highlights:
Having worked with esteemed companies such as Eliem Therapeutics, Inc. and Athenen Therapeutics, Inc., Neil Buckley has honed his expertise in developing cutting-edge pharmaceutical solutions. His commitment to pushing the boundaries of neuropharmacology is exemplified through his patent portfolio and industry collaborations.
Collaborations:
Throughout his career, Buckley has collaborated with various industry experts, including his coworker Andrew D Levin. Together, they have contributed to the advancement of neurosteroid research, paving the way for novel therapeutic interventions in the realm of GABAreceptor modulation.
Conclusion:
In conclusion, Neil Buckley's innovative work in neurosteroid compositions and GABAreceptor modulation underscores his dedication to pioneering advancements in neuropharmacology. His patents reflect a commitment to improving treatment modalities for GABAdisorders, solidifying his position as a visionary inventor in the field.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile